CTIC CTI BioPharma Corp.

2.5
+0.07  (+3%)
Previous Close 2.43
Open 2.45
52 Week Low 0.9629
52 Week High 4.13
Market Cap $233,205,530
Shares 93,282,212
Float 71,245,124
Enterprise Value $189,443,842
Volume 639,091
Av. Daily Volume 540,195
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Pacritinib (PRE-VENT)
COVID-19
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Pacritinib
Myelofibrosis
PDUFA priority review
PDUFA priority review
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Pacritinib
Graft Vs Host Disease
Phase 1/2
Phase 1/2
Phase 1/2 data presented at ASH December 6, 2020.
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 3
Phase 3
Phase 3 data released July 9. 2018. Primary endpoint not met.
OPAXIO
Ovarian cancer
Phase 3
Phase 3
Phase 3 - noted July 2016 that unlikely to have survival benefit

Latest News

  1. SEATTLE, July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

    To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 6891246. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available…

    SEATTLE, July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

    To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 6891246. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Argot Partners

    +212-600-1902

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-report-second-quarter-2021-financial-results-on-august-5-2021-301344010.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  2. SEATTLE, July 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on July 23, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 68,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment…

    SEATTLE, July 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on July 23, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 68,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301341364.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  3. SEATTLE, July 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on July 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employee received options to purchase 12,000 shares of CTI BioPharma common stock. The options will be issued upon the employee's grant date (the "Grant Date"), and all stock options…

    SEATTLE, July 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on July 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employee received options to purchase 12,000 shares of CTI BioPharma common stock. The options will be issued upon the employee's grant date (the "Grant Date"), and all stock options included within the equity inducement award will have an exercise price equal to the closing price of CTI BioPharma common stock on the Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301328506.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  4. SEATTLE, June 23, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on June 23, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 25,500 shares of CTI BioPharma common stock. The options will be issued upon each employee's grant date (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301318734.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  5. SEATTLE, June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on June 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 47,500 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock…

    SEATTLE, June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on June 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 47,500 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301309539.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
View All CTI BioPharma Corp. News